A Science and Technology Blog
Preliminary data, which is yet to be peer-reviewed, shows molnupiravir can reduce risk of hospitalisation or death by 50% in non-hospitalised adult patients with mild-to-moderate COVID-19 disease. The trial included…
Precious time was wasted before critical facilities began to be scaled up to meet the demands of the second wave that is accelerating at an unprecedented speed leading to healthcare…
According to a preliminary report posted on December 19 by the COG-UK Consortium scientists, as of December 15, 1,623 variant genomes have been sequenced. In a December 21 tweet, COG-UK…
Even as WHO supported Solidarity Therapeutics Trial found remdesivir to be ineffective in reducing mortality and duration of hospital stay, the global body prequalified the drug the same day the…
WHO’s Solidarity Therapeutics Trial, the largest randomised control trial carried out in the world during the pandemic, has found that four repurposed drugs — remdesivir, interferon, hydroxychloroquine and lopinavir/ritonavir regimes…
Gilead plans to begin a Phase-1 clinical trial in August of an inhaled version of remdesivir for early-stage COVID-19 treatment outside of hospital settings. The drug is currently approved for…
Treating severe COVID-19 patients with the antiviral drug remdesivir does not quicken recovery, the first randomised, placebo-controlled, double-blind trial found. Although not statistically significant, those treated with the drug within…
Science Chronicle 